|
|
FOR IMMEDIATE RELEASE July 14, 2003 Guava Technologies Inc., a biotechnology company providing life science researchers easy-to-use, affordable single cell analysis solutions, today reported record sales growth for the first half of fiscal year 2003. Guava Technologies Announces Record Revenues for the First Half of 2003 ... Guava Technologies Inc., a biotechnology company providing life science researchers easy-to-use, affordable single cell analysis solutions, today reported record sales growth for the first half of fiscal year 2003. Revenues for the first six months of 2003 marked the largest two quarters in Guava Technologies' history, up 60% in revenue, 100% in reagent sales and 55% in the number of systems sold from the same period of 2002. "Our success this year reflects a strong interest from researchers in the growing list of applications for Guava's personal cell analysis systems," said Rajen Dalal, president and chief executive officer of Guava Technologies. "First time and repeat customers are discovering that our compact, easy-to-use analysis platform can provide timely, high-quality results that significantly accelerate the pace of their efforts, both in the research lab and in the cell processing facility." First Half of 2003 Highlights Highlights of the first half of 2003 included Guava Technologies adding more than 20 new pharmaceutical and biotechnology companies to its customer base, giving the company's products a presence at 15 of the top 20 pharmaceutical companies and 8 of the top 10 biotechnology companies. Furthermore Guava launched its new Guava PCA-96 system, the first 96-well microplate cell analysis system designed to satisfy the needs of researchers in drug discovery. Guava also greatly broadened the usefulness of its cell analysis systems by releasing several new applications including a suite of three assays for measuring different stages of apoptosis (programmed cell death). In addition, Guava's applications were cited in three peer-reviewed scientific journals including *Nature Genetics, **Immunity and ***Oncogenomics. "The Guava Annexin V assay and Guava PCA were key tools in studies that led to our discovery that two genetic variants of p53 are markedly different in their ability to induce cell death by apoptosis," said Maureen Murphy, Ph.D., whose team from Fox Chase Cancer Center published its findings in the March 2003 issue of Nature Genetics. "The ability to distinguish quickly and quantitatively between healthy cells and those entering the earliest stages of cell death using the Guava system was a great research advantage." The Guava PCA Systems The Guava PCA systems simplify cell analysis in a single, powerful benchtop system that scientists in the lab can use with less than one day of training requiring only a few microliters of sample volume, saving precious and expensive cells, reagents, and compounds. The Guava PCA systems are flexible, highly affordable, and ultra-compact. Unlike traditional cell analysis systems, the Guava PCA systems produce high-content, single cell analysis from a single well or tube right at the benchtop. This gives researchers comprehensive test results-fast-thus streamlining the entire R&D and drug discovery process. About Guava Technologies Based in Hayward, California, Guava Technologies is a biotechnology company that develops, manufactures and markets patented, integrated cellular analysis systems for the life science researcher's benchtop. The company is revolutionizing the way that cell culture monitoring and cell screening assays are performed, by providing highly miniaturized microliter scale systems that make common assays in cell-based analysis accessible at the benchtop. Guava's products have broad applications to life sciences research, drug discovery and biopharmaceutical production today, but also offer potential for use in clinical testing and blood processing, as well as other areas where single cell analysis is important. More information about the company and its products is available at www.guavatechnologies.com. Guava, Guava Technologies and ViaCount are registered trademarks of Guava Technologies, Inc. PCA, Nexin, and MultiCaspase are trademarks of Guava Technologies, Inc. *
The codon 72 polymorphic variants of p53 have markedly different
apoptotic potential.
CONTACTS:
|
Home | News | CombiChem | CombiChem Links | HTS | Lab Automation
Sales | Email Us | Repairs | Disclaimer | © 1999-2004